Detalhe da pesquisa
1.
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Am J Respir Crit Care Med
; 208(4): 406-416, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364283
2.
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Am J Respir Crit Care Med
; 208(4): 417-427, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37411039
3.
Reply to Gan et al., to Calzetta et al., and to Poor.
Am J Respir Crit Care Med
; 209(2): 226-228, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939377
4.
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
COPD
; 13(1): 1-10, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26451734
5.
Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease.
PLoS One
; 17(8): e0273170, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969632
6.
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Respir Med
; 205: 107040, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470149
7.
Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD.
Pulm Ther
; 7(2): 503-516, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34232493
8.
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Chronic Obstr Pulm Dis
; 8(1)2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33156982
9.
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.
Chronic Obstr Pulm Dis
; 7(2): 99-106, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324981
10.
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Int J Chron Obstruct Pulmon Dis
; 13: 1483-1494, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773947
11.
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 µg versus once-daily vilanterol 25 µg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Respir Med
; 123: 8-17, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28137501
12.
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Chest
; 151(2): 340-357, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27916620
13.
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD.
Int J Chron Obstruct Pulmon Dis
; 11: 971-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27274218
14.
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.
Chronic Obstr Pulm Dis
; 3(2): 549-559, 2016 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28848879
15.
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Respir Med
; 109(9): 1155-63, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26117292
16.
Once-daily indacaterol 75 µg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
Int J Chron Obstruct Pulmon Dis
; 9: 919-25, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25214778